Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists. Lyle Craker, Ph.D., Reddit awarded $82,765.95

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Meadow

JULY 13, 2018

19:05) What equity programs are currently in place in each of your cities and why are they important to you and your city? (25:28) 25:28) Going beyond equity programs, have there been conversations about creating more diversity in the cannabis industry in your respective cities?

Wellness and Beauty 40

Wellness and Beauty Policy Consumption Cannabis 40

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. 6059, 6074, 6075, 6077(a), (b), 6253, Nov. 18, 1988 , 102 Stat. 101–189, div.

Banking 45

Banking Law Marijuana State Laws 45